secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shattuck Labs, Inc. (STTK)
CIK:        0001680367
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0001680367-25-000030
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shattuck Labs Q1 net loss $13.7M, cash $60.9M; SL-325 IND filing expected Q3 2025
--------------------------------------------------------------------------------

- Net loss of $13.7M ($0.27 per share) for Q1 2025 compared to $18.5M ($0.37 per share) in Q1 2024.
- Cash and equivalents of $60.9M as of Mar 31, 2025, expected to fund operations into 2027.
- SL-325 IND filing expected in Q3 2025; Phase 1 SAD portion first patient in Q3 2025, enrollment complete Q2 2026.
- R&D expenses decreased to $9.9M from $16.3M YoY; G&A expenses decreased to $4.5M from $4.9M.
- Wind-down activities for discontinued oncology programs substantially completed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680367/000168036725000030/0001680367-25-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680367/000168036725000030/sttk-20250501.htm
  HTML page:      https://secwatch.observer/filing/0001680367-25-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer